Intrinsiqq
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA Financials

NYKD.XOSL

Compare

All currency values in $ millions unless otherwise noted

Scroll

Income Statement
TTM
DEC 2025
DEC 2024
DEC 2023
DEC 2022
DEC 2021
Revenues
Revenue$0$0$9$13$7$34
Total Operating Expenses––$57$71––
Operating Income-$28-$29-$48-$58-$53-$11
Non-Operating
Net Interest Expense-$0-$0-$6-$5-$0-$0
Other Non-Operating Income (Expense)––$9$19––
EBT (Earnings Before Tax)––-$46-$44––
Income Tax Expense-$1-$5-$7-$9-$8-$2
Earnings from Continuing Ops––-$39-$35––
Net Income
Net Income-$23-$12-$39-$35-$43-$9
Per Share Data
Revenue Per Share$0.00$0.00$0.03$0.04$0.03$0.11
EPS (Basic)-$0.06-$0.04-$0.12-$0.12-$0.15-$0.03
EPS (Diluted)-$0.06-$0.04-$0.12-$0.12-$0.15-$0.03
Shares Outstanding359.3M306.0M323.5M292.9M285.0M313.8M
Dividends Per Share$0.00$0.00$0.10$0.00$0.00$0.00

Nykode Therapeutics ASA (NYKD.XOSL) financials: revenue, profit and margins

Nykode Therapeutics ASA (NYKD.XOSL) generated about $0.00 in revenue and -$23 million in net income over the trailing twelve months, growing at roughly -36.5% a year. Figures are from company filings; this is analysis, not investment advice.

Frequently asked

What is Nykode Therapeutics ASA's (NYKD.XOSL) revenue?+

Nykode Therapeutics ASA generated about $0.00 in revenue over the trailing twelve months. Revenue has grown at roughly -36.5% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Nykode Therapeutics ASA profitable?+

Nykode Therapeutics ASA reported about -$23 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How fast is Nykode Therapeutics ASA growing?+

Nykode Therapeutics ASA's revenue has compounded at roughly -36.5% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside NYKD.XOSL's margins and free cash flow. This is analysis from company filings, not investment advice.

How the market compares: How many US companies are profitable

Peers

Biotechnology · Pick stocks to compare with NYKD.XOSL

CompareIntrinsic value
SOFTX.XOSLSoftOx Solutions AS
€0.01+0.00%10
HBC.XOSLHofseth BioCare ASA
€0.09+0.00%30
NAVA.XOSLNavamedic ASA
€0.95-3.85%29
ONCIN.XOSLOncoinvent ASA
kr 72.20+7.12%50
ZLNA.XOSLZelluna ASA
€1.33-5.67%20
VISTN.XOSLVistin Pharma ASA
€1.76+0.57%81
PHO.XOSLPhotocure ASA
kr 40.85-2.85%88
OMDA.XOSLOmda A/S
€4.07-0.25%42

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing NYKD.XOSL

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.